Katharine Barnard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4257443/publications.pdf

Version: 2024-02-01

105 papers 3,878 citations

147726 31 h-index 59 g-index

109 all docs

109 docs citations 109 times ranked 4018 citing authors

#	Article	IF	CITATIONS
1	User and Healthcare Professional Perspectives on Do-It-Yourself Artificial Pancreas Systems: A Need for Guidelines. Journal of Diabetes Science and Technology, 2022, 16, 224-227.	1.3	9
2	Feasibility of Spotlight Consultations Tool in Routine Care: Real-World Evidence. Journal of Diabetes Science and Technology, 2022, 16, 939-944.	1.3	3
3	RESCUE Collaborative Community: A New Initiative to Reduce Rates of Intended Self-Injury and Suicide Among People with Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 583-587.	2.4	2
4	AiDAPT: automated insulin delivery amongst pregnant women with type 1 diabetes: a multicentre randomized controlled trial – study protocol. BMC Pregnancy and Childbirth, 2022, 22, 282.	0.9	16
5	Diabetes Technologies and the Human Factor. Diabetes Technology and Therapeutics, 2022, 24, S-173-S-183.	2.4	1
6	Protocol paper: multi-Centre randomised controlled trial evaluating a pre-clinic diabetes assessment and mapped care planning intervention amongst adults with type 1 , type 2 or pre-diabetes. Trials, 2022, 23 , .	0.7	0
7	The use of liraglutide 3.0Âmg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 1262-1271.	2.2	28
8	The Optimising Cardiac Surgery ouTcOmes in People with diabeteS (OCTOPuS) randomised controlled trial to evaluate an outpatient pre-cardiac surgery diabetes management intervention: a study protocol. BMJ Open, 2021, 11, e050919.	0.8	5
9	Diabetes Technology and the Human Factor. Diabetes Technology and Therapeutics, 2021, 23, S-169-S-178.	2.4	О
10	Flash glucose monitoring with the FreeStyle Libre 2 compared with self-monitoring of blood glucose in suboptimally controlled type 1 diabetes: the FLASH-UK randomised controlled trial protocol. BMJ Open, 2021, 11, e050713.	0.8	7
11	Developing an intervention to optimise the outcome of cardiac surgery in people with diabetes: the OCTOPuS pilot study. Pilot and Feasibility Studies, 2021, 7, 157.	0.5	1
12	Injection Technique: Development of a Novel Questionnaire and User Guide. Diabetes Spectrum, 2021, 34, 156-165.	0.4	3
13	Development of a Novel Tool to Support Engagement With Continuous Glucose Monitoring Systems and Optimize Outcomes. Journal of Diabetes Science and Technology, 2020, 14, 151-154.	1.3	3
14	Suicide and Self-inflicted Injury in Diabetes: A Balancing Act. Journal of Diabetes Science and Technology, 2020, 14, 1010-1016.	1.3	16
15	Exercising with an automated insulin delivery system: qualitative insight into the hopes and expectations of people with type 1 diabetes. Practical Diabetes, 2020, 37, 19-23.	0.1	1
16	A standard set of personâ€centred outcomes for diabetes mellitus: results of an international and unified approach. Diabetic Medicine, 2020, 37, 2009-2018.	1.2	62
17	Social Inequality and Diabetes: A Commentary. Diabetes Therapy, 2020, 11, 803-811.	1.2	32
18	An Intolerable Burden: Suicide, Intended Self-Injury and Diabetes. Canadian Journal of Diabetes, 2020, 44, 541-544.	0.4	6

#	Article	IF	CITATIONS
19	Diabetes Technologies and the Human Factor. Diabetes Technology and Therapeutics, 2020, 22, S-130-S-140.	2.4	0
20	Psychosocial aspects of diabetes technology. Diabetic Medicine, 2020, 37, 448-454.	1.2	22
21	You, me, and diabetes: Intimacy and technology among adults with T1D and their partners Families, Systems and Health, 2020, 38, 418-427.	0.4	7
22	Utilizing eHealth and Telemedicine Technologies to Enhance Access and Quality of Consultations: It's Not What You Say, It's the Way You Say It. Diabetes Technology and Therapeutics, 2019, 21, S2-41-S2-47.	2.4	7
23	Supporting Good Intentions With Good Evidence: How to Increase the Benefits of Diabetes Social Media. Journal of Diabetes Science and Technology, 2019, 13, 974-978.	1.3	16
24	Diabetes Technology and the Human Factor. Diabetes Technology and Therapeutics, 2019, 21, S-138-S-147.	2.4	5
25	Assessing patientâ€reported outcomes for automated insulin delivery systems: the psychometric properties of the ⟨scp⟩INSPIRE⟨/scp⟩ measures. Diabetic Medicine, 2019, 36, 644-652.	1.2	59
26	Diabetes and male sexual health: an unmet challenge. Practical Diabetes, 2019, 36, 201-206.	0.1	5
27	STructured lifestyle education for people With SchizophrEnia (STEPWISE): mixed methods process evaluation of a group-based lifestyle education programme to support weight loss in people with schizophrenia. BMC Psychiatry, 2019, 19, 358.	1.1	13
28	Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial. Trials, 2019, 20, 633.	0.7	15
29	Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. British Journal of Psychiatry, 2019, 214, 63-73.	1.7	77
30	Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care, 2018, 41, 1391-1399.	4.3	113
31	Diabetes Technology and the Human Factor. Diabetes Technology and Therapeutics, 2018, 20, S-128-S-138.	2.4	8
32	Automated Insulin Delivery Systems: Hopes and Expectations of Family Members. Diabetes Technology and Therapeutics, 2018, 20, 222-228.	2.4	22
33	Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology, 2018, 12, 634-638.	1.3	22
34	Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study. Trials, 2018, 19, 665.	0.7	11
35	Barriers and facilitators to taking on diabetes self-management tasks in pre-adolescent children with type 1 diabetes: a qualitative study. BMC Endocrine Disorders, 2018, 18, 71.	0.9	34
36	Diabetes Technological Revolution: Winners and Losers?. Journal of Diabetes Science and Technology, 2018, 12, 1227-1230.	1.3	8

3

#	Article	IF	CITATIONS
37	Open Source Closed-Loop Insulin Delivery Systems: A Clash of Cultures or Merging of Diverse Approaches?. Journal of Diabetes Science and Technology, 2018, 12, 1223-1226.	1.3	32
38	Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technology Assessment, 2018, 22, 1-160.	1.3	39
39	Development of an acceptable and feasible selfâ€management group for children, young people and families living with Type 1 diabetes. Diabetic Medicine, 2017, 34, 813-820.	1.2	12
40	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technology and Therapeutics, 2017, 19, 391-399.	2.4	45
41	What End Users and Stakeholders Want From Automated Insulin Delivery Systems. Diabetes Care, 2017, 40, 1453-1461.	4.3	45
42	Managing diabetes in preschool children. Pediatric Diabetes, 2017, 18, 499-517.	1.2	73
43	Experiences of closedâ€loop insulin delivery among pregnant women with Type 1 diabetes. Diabetic Medicine, 2017, 34, 1461-1469.	1.2	44
44	Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care, 2017, 40, 63-68.	4.3	141
45	A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technology Assessment, 2017, 21, 1-278.	1.3	42
46	Web-Based Management Trial of Diabetes Care. Diabetes Technology and Therapeutics, 2016, 18, 605-606.	2.4	0
47	STEPWISE – STructured lifestyle Education for People WIth SchizophrEnia: a study protocol for a randomised controlled trial. Trials, 2016, 17, 475.	0.7	12
48	Impact of Type 1 Diabetes Technology on Family Members/Significant Others of People With Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 824-830.	1.3	52
49	Impact of Chronic Sleep Disturbance for People Living With T1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 762-767.	1.3	28
50	Diabetes and Partners. Diabetes Technology and Therapeutics, 2016, 18, 278-279.	2.4	2
51	Parents' information and support needs when their child is diagnosed with type 1 diabetes: a qualitative study. Health Expectations, 2016, 19, 580-591.	1.1	40
52	Psychosocial Aspects and Diabetes Technology – Head to Head or Hand in Hand?. European Endocrinology, 2016, 12, 35.	0.8	1
53	Challenges of optimizing glycaemic control in children with Type 1 diabetes: a qualitative study of parents' experiences and views. Diabetic Medicine, 2015, 32, 1063-1070.	1.2	35
54	Is iatrogenic sleep disturbance worth the effort in TypeÂ1 diabetes?. Diabetic Medicine, 2015, 32, 984-986.	1.2	8

#	Article	IF	Citations
55	Psychosocial aspects of closed―and openâ€loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting. Diabetic Medicine, 2015, 32, 601-608.	1.2	91
56	A decade in diabetes specialist services, 2000 to 2011, in England: the views of consultant diabetologists and diabetes specialist nurses amidst persistent healthcare delivery change. Diabetic Medicine, 2015, 32, 1662-1666.	1.2	3
57	PsychDT Working Group. Journal of Diabetes Science and Technology, 2015, 9, 925-928.	1.3	13
58	Could the Discrepancy in Perceived Emotional Care Received and Provided Be a Barrier to Active Diabetes Self-management? Insights From the Second Diabetes Attitudes, Wishes and Needs (DAWN2) Study. Diabetes Care, 2015, 39, dc150674.	4.3	2
59	Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want?. Diabetes Technology and Therapeutics, 2015, 17, 311-315.	2.4	42
60	High Reported Treatment Satisfaction in People With Type 1 Diabetes Switching to Latest Generation Insulin Pump Regardless of Previous Therapy. Journal of Diabetes Science and Technology, 2015, 9, 231-236.	1.3	15
61	Safe and Efficacious Use of Automated Bolus Advisors in Individuals Treated With Multiple Daily Insulin Injection (MDI) Therapy. Journal of Diabetes Science and Technology, 2015, 9, 1138-1142.	1.3	12
62	Patient-Reported Outcomes and Continuous Glucose Monitoring: Can We Do Better With Artificial Pancreas Devices?. Diabetes Care, 2015, 38, e70-e70.	4.3	10
63	Unsupervised overnight closed loop insulin delivery during free living: analysis of randomised cross-over home studies in adults and adolescents with type 1 diabetes. Lancet, The, 2015, 385, S96.	6.3	18
64	Holistic Impact of Closed-Loop Technology on People With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 932-933.	1.3	16
65	Psychosocial Assessment of Artificial Pancreas (AP): Commentary and Review of Existing Measures and Their Applicability in AP Research. Diabetes Technology and Therapeutics, 2015, 17, 295-300.	2.4	39
66	Parents' experiences of managing their child's diabetes using an insulin pump: a qualitative study. Diabetic Medicine, 2015, 32, 627-634.	1.2	18
67	Unsupervised home use of an overnight closedâ \in loop system over 3â \in "4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 452-458.	2.2	26
68	Technological Advancement in the Treatment of Diabetesâ€"Ignoring Psychosocial Impact at Our Peril. Diabetes Technology and Therapeutics, 2015, 17, 149-151.	2.4	6
69	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. Diabetes Care, 2015, 38, 1627-1633.	4.3	28
70	The Role of Mobile Applications in Improving Alcohol Health Literacy in Young Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1313-1320.	1.3	25
71	Home Use of an Artificial Beta Cell in Type 1 Diabetes. New England Journal of Medicine, 2015, 373, 2129-2140.	13.9	397
72	Pathways to diagnosis: a qualitative study of the experiences and emotional reactions of parents of children diagnosed with type 1 diabetes. Pediatric Diabetes, 2014, 15, 591-598.	1.2	21

#	Article	IF	Citations
73	Comment on Doyle et al. Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms. Diabetes Care 2014;37:1191–1197. Diabetes Care, 2014, 37, e226-e227.	4.3	8
74	Use of an Insulin Bolus Advisor Facilitates Earlier and More Frequent Changes in Insulin Therapy Parameters in Suboptimally Controlled Patients with Diabetes Treated with Multiple Daily Insulin Injection Therapy: Results of the ABACUS Trial. Diabetes Technology and Therapeutics, 2014, 16, 310-316.	2.4	19
75	Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol. BMJ Open, 2014, 4, e006075-e006075.	0.8	12
76	The Relative Effectiveness of Pumps Over MDI and Structured Education (REPOSE): study protocol for a cluster randomised controlled trial. BMJ Open, 2014, 4, e006204-e006204.	0.8	20
77	Kaleidoscope model of diabetes care: time for a rethink?. Diabetic Medicine, 2014, 31, 522-530.	1.2	27
78	Perceptions and experiences of using automated bolus advisors amongst people with type 1 diabetes: A longitudinal qualitative investigation. Diabetes Research and Clinical Practice, 2014, 106, 443-450.	1.1	25
79	Alcohol health literacy in young adults with Type 1 diabetes and its impact on diabetes management. Diabetic Medicine, 2014, 31, 1625-1630.	1.2	33
80	Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Research and Care, 2014, 2, e000025.	1.2	132
81	Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes and Endocrinology,the, 2014, 2, 701-709.	5.5	140
82	Interview: A psychologist's view of diabetes care. Diabetes Management, 2014, 4, 243-245.	0.5	0
83	Use of an Insulin Bolus Advisor Improves Glycemic Control in Multiple Daily Insulin Injection (MDI) Therapy Patients With Suboptimal Glycemic Control. Diabetes Care, 2013, 36, 3613-3619.	4.3	95
84	Bibliometrics of systematic reviews: analysis of citation rates and journal impact factors. Systematic Reviews, 2013, 2, 74.	2.5	84
85	Antidepressant Medication as a Risk Factor for Type 2 Diabetes and Impaired Glucose Regulation. Diabetes Care, 2013, 36, 3337-3345.	4.3	140
86	Social Networking and Understanding Alcohol-Associated Risk for People with Type 1 Diabetes: Friend or Foe?. Diabetes Technology and Therapeutics, 2013, 15, 308-314.	2.4	31
87	Use of Automated Bolus Advisors May Improve Adherence to Multiple Daily Insulin Injection Therapy. Journal of Diabetes Science and Technology, 2012, 6, 1233-1234.	1.3	2
88	Implementing psychological assessments required by the Best Practice Tariff for Paediatric Diabetes. Practical Diabetes, 2012, 29, 335-338.	0.1	1
89	Use of an Automated Bolus Calculator Reduces Fear of Hypoglycemia and Improves Confidence in Dosage Accuracy in Patients with Type 1 Diabetes Mellitus Treated with Multiple Daily Insulin Injections. Journal of Diabetes Science and Technology, 2012, 6, 144-149.	1.3	81
90	Automated bolus advisor control and usability study (ABACUS): does use of an insulin bolus advisor improve glycaemic control in patients failing multiple daily insulin injection (MDI) therapy? [NCT01460446]. BMC Family Practice, 2012, 13, 102.	2.9	15

#	Article	IF	CITATIONS
91	How to reduce the risk of failing to reach recruitment targets: lessons learnt from a pump pilot trial. Diabetic Medicine, 2012, 29, 1600-1601.	1.2	1
92	Psychosocial support for people with diabetes: past, present and future. Diabetic Medicine, 2012, 29, 1358-1360.	1.2	39
93	Time to embrace a new approach to diabetes care?. Practical Diabetes, 2012, 29, 181-181.	0.1	0
94	Alcoholâ€associated risks for young adults with Typeâ $€f1$ diabetes: a narrative review. Diabetic Medicine, 2012, 29, 434-440.	1.2	33
95	Developing a matrix to identify and prioritise research recommendations in HIV Prevention. BMC Public Health, $2011,11,381.$	1.2	6
96	The Southampton Initiative for Health. Journal of Health Psychology, 2011, 16, 178-191.	1.3	55
97	Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatrics, 2010, 10, 50.	0.7	188
98	Not all roads lead to Romeâ€"a review of quality of life measurement in adults with diabetes. Diabetic Medicine, 2009, 26, 315-327.	1.2	202
99	Crossâ€sectional study into quality of life issues surrounding insulin pump use in type 1 diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2008, 25, 194-200.	0.2	20
100	Quality of life and impact of continuous subcutaneous insulin infusion for children and their parents. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2008, 25, 278-283.	0.2	29
101	Effectiveness of a computerised assessment tool to prompt individuals with diabetes to be more active in consultations. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 36-41.	0.2	7
102	Qualitative study into quality of life issues surrounding insulin pump use in type 1 diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 143-148.	0.2	21
103	Patient and professional accuracy of recalled treatment decisions in out-patient consultations. Diabetic Medicine, 2007, 24, 557-560.	1.2	32
104	Does professional-centred training improve consultation outcomes?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2006, 23, 253-256.	0.2	1
105	The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabetic Medicine, 2006, 23, 445-448.	1.2	294